The FDA cleared Medtronic’s MiniMed Go Smart Multiple Daily Injection (MDI) system in January 2026, a move that folds two previously separate pieces of diabetes technology into a single smartphone experience. The system links the company’s InPen smart insulin pen with Abbott’s Instinct continuous glucose monitoring (CGM) sensors, streaming real-time glucose data and dosing recommendations into one dashboard rather than forcing patients to toggle between apps.
Who the clearance covers
The clearance applies to people age 7 and older who have insulin-requiring type 1 or type 2 diabetes and manage their condition with multiple daily injections rather than a pump. Medtronic also secured clearance for children ages 2 to 6, provided a caregiver or other adult supervises use. That pediatric allowance matters: young children with type 1 diabetes are among the hardest patients to manage safely, since they cannot reliably self-report symptoms of low or high blood sugar.
How the pieces fit together
InPen already tracked insulin doses electronically and calculated suggested doses based on a patient’s settings. Instinct, Abbott’s CGM line, independently tracked glucose trends. What’s new is the integration: the smart pen now receives live glucose readings from the sensor and can factor them directly into its dosing suggestions, while the combined app displays glucose trends, injection history, and active insulin in one place. For patients managing multiple daily injections, that consolidation removes a layer of manual math and cross-referencing that previously fell on the patient.
The bigger shift: fighting diabetes distress
Diabetes management has long demanded near-constant vigilance — checking glucose, calculating carbohydrate ratios, timing injections, and adjusting for exercise or illness. Clinicians increasingly describe the cumulative toll of that vigilance as “diabetes distress,” a recognized psychological burden distinct from depression that is associated with worse blood sugar control. The MiniMed Go Smart MDI clearance fits a broader pattern across the industry in 2026: CGM makers, smart-pen companies, and software developers are converging on unified, AI-assisted dashboards specifically to reduce that cognitive load, rather than simply adding more raw data for patients to interpret themselves.
Where the limits are
The system is a decision-support tool, not an automated insulin-delivery pump — it still requires the patient or caregiver to physically administer each injection, unlike closed-loop pump systems that adjust insulin delivery automatically. That means the technology reduces calculation burden but not the physical burden of injections, and it depends on patients consistently wearing the CGM sensor and carrying the smart pen for the integration to deliver its full value. Cost and insurance coverage for the combined system, which pairs a Medtronic device with an Abbott sensor across two manufacturers, will also determine how quickly it reaches patients who could benefit most.
Why cross-company integration is unusual
Medical device companies have historically built closed ecosystems, encouraging patients to buy every component — sensor, pen, pump, and software — from a single vendor. Medtronic pairing its own InPen with a competitor’s CGM sensor line marks a departure from that pattern, and reflects growing pressure from patients, clinicians, and regulators to prioritize interoperability over vendor lock-in. For patients, that can mean more flexibility to choose the CGM sensor that fits their skin, insurance coverage, or comfort preferences, without having to abandon the injection-tracking tools they’ve already learned to use.
What’s next
Medtronic is expected to roll the system out through diabetes clinics and endocrinology practices over the coming months, with real-world data likely to surface as adoption grows. The clearance also signals more cross-company hardware pairings ahead, as CGM and injection-device makers increasingly build interoperable systems rather than closed ecosystems. For the roughly 1.6 million Americans living with type 1 diabetes and the far larger population managing insulin-dependent type 2 diabetes, the practical test will be whether a single dashboard actually reduces daily burden — or simply relocates it into a new app. Clinicians will also be watching whether the dosing recommendations generated from combined CGM and pen data measurably improve blood sugar control over time, since a cleaner interface is only valuable if it translates into fewer dangerous highs and lows. Insurers and health systems will also be watching adoption closely, since the long-term case for covering combined smart-pen and CGM systems rests on whether they measurably reduce costly emergency visits tied to severe hypoglycemia or hyperglycemia, not simply on whether patients report an easier daily routine.
